For the study, researchers obtained fresh blood and ACL remnants from four patients undergoing ACL reconstruction surgery. Platelet-poor plasma and platelet-rich plasma were prepared from the samples with various growths concentration factors.
Researchers found that the concentration of the main growth factors were higher in the platelet-rich clot than the platelet-poor clot. The in vitro treatment of ACL cells with platelet-rich clot releasate resulted in a significant increase in cell number, and the total collagen production by the platelet-rich clot releasate-treated cells was significantly higher because of the enhanced cell proliferation.
There was no significant effect of the platelet-rich clot releasate treatment on gene expression for type-I collagen. However, type-III collagen was significantly enhanced, according to the report.
Read the abstract for “Effects of Autologous Platelet-Rich Plasma on Cell Viability and Collagen Synthesis in Injured Human Anterior Cruciate Ligament.”
Read other coverage on sports medicine studies:
– Study Shows ACI Treatment Outcomes Similar Between Older and Younger Patients
– Study: Osteochondral Grafts May Be Safe for Young Knee Replacement Patients
– Study: PRFM Makes Little Long-Term Difference When Performing Arthroscopic Rotator Cuff Repair
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
